Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 6/20 | 0.68 |
| ▸ | ESR1 | P03372 | 5/20 | 0.68 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.62 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.62 |
| ▸ | CACNG2 | Q9Y698 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.44 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2328330 | 0.95 | ESR2 (0.70) | ESR2ESR1GRIA1CACNG8CACNG2 | |
| SCHEMBL2330800 | 0.93 | ESR1 (0.59) | ESR2ESR1GRIA1CACNG8CACNG2 | |
| SCHEMBL4589408 | 0.93 | ESR1 (0.71) | ESR2ESR1GRIA1CACNG8CACNG2 | |
| SCHEMBL2323575 | 0.92 | ESR1 (0.58) | ESR2ESR1GRIA1CACNG8CACNG2 | |
| SCHEMBL2328740 | 0.90 | ESR1 (0.59) | ESR2ESR1GRIA1CACNG8CACNG2 | |
| SCHEMBL5579900 | 0.88 | ESR1 (0.68) | ESR2ESR1GRIA1CACNG8CACNG2 | |
| SCHEMBL8021778 | 0.88 | ESR2 (0.88) | ESR2ESR1GRIA1CACNG8CACNG2 | |
| SCHEMBL8021233 | 0.88 | ESR2 (0.53) | ESR2ESR1GRIA1CACNG8CACNG2 | |
| SCHEMBL2330121 | 0.87 | ESR1 (0.68) | ESR2ESR1GRIA1CACNG8CACNG2 | |
| SCHEMBL10047632 | 0.86 | ESR2 (0.85) | ESR2ESR1GRIA1CACNG8CACNG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070004713-A1 | Therapeutic benimidazole compounds | ASTRAZENECA AB (SE) | 2007-01-04 | — | — | US | disclosed |
| EP-1341768-A1 | THERAPEUTIC BENZIMIDAZOLE COMPOUNDS | AstraZeneca AB (SE) | 2003-09-10 | — | — | EP | disclosed |
| WO-2002046168-A1 | THERAPEUTIC BENZIMIDAZOLE COMPOUNDS | ASTRAZENECA AB (SE) | 2002-06-13 | — | — | WO | disclosed |
| US-6030992-A | ANTAGONISTS FOR THE BINDING OF NEUROKININ-2 RECEPTOR; SLEEP DISORDERS; BENZIMIDES, 2- OR 3-ALKOXYBENZIMIDES AND 2,3-DIALKOXYBENZIMIDES | ELI LILLY AND COMPANY (US) | 2000-02-29 | — | — | US | disclosed |
| US-6025379-A | A SUBSTITUTED BENZIMIDAZOLE, TACHYKININ RECEPTOR ANTAGONISTS, | ELI LILLY AND COMPANY (US) | 2000-02-15 | — | — | US | disclosed |
| WO-1997033873-A1 | METHODS OF TREATING OR PREVENTING INTERSTITIAL CYSTITIS | ELI LILLY AND COMPANY (US) | 1997-09-18 | — | — | WO | disclosed |
| US-5552426-A | NERVOUS SYSTEM DISORDERS USING IMIDAZOLE DERIVITIVES | ELI LILLY AND COMPANY (US) | 1996-09-03 | — | — | US | disclosed |
| EP-0694535-A1 | Non-peptidyl tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 1996-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004713-A1 | Therapeutic benimidazole compounds | ESR2, ESRRA, ESRRB | ESR2 1/4885ESR1 6/4885GRIA1 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.